Lucia Masarova, MD

home / authors / lucia-masarova-md

Articles

Lucia Masarova, MD

Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia

Lucia Masarova, MD
August 15th 2023

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Read More

Lucia Masarova, MD

Dr Masarova on the Rationale for Investigating Ropeginterferon Alfa-2b in Essential Thrombocythemia

Lucia Masarova, MD
June 13th 2023

Lucia Masarova, MD, discusses the single-arm multicenter phase 2 EXCEED-ET trial of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia.

Read More

Lucia Masarova, MD

Dr. Masarova on Future Research in MPNs

Lucia Masarova, MD
October 19th 2020

Lucia Masarova, MD, discusses future research ​efforts in myeloproliferative neoplasms.

Read More

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

Dr. Masarova on the Safety of JAK Inhibitor/Targeted Therapy Combos in Myelofibrosis

Lucia Masarova, MD
October 5th 2020

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

Read More

Latest Updated Articles

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 3rd 2024
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC